ARVO 2024: Dr. Michael Chaglasian on the Monaco OCT's success in glaucoma detection

News
Video

Michael Chaglasian, OD, details results from a study that assessed the new Monaco OCT's efficacy in glaucoma detection alongside ultra wideview imaging.

In an interview with the Eye Care Network, Michael Chalasian, OD, detailed findings from a study that concluded that the new Monaco optical coherence tomography (OCT) combined with ultra widefield imaging from Optos was successfully able to detect glaucoma in patients. He presented this data in his presentation "Detection of glaucoma with a novel widefield imaging device combined with OCT" at the annual Association for Research in Vision and Ophthalmology meeting in Seattle, Washington.

Video Transcript

Editor’s note - The following transcript has been lightly edited for clarity.

Michael Chaglasian, OD:

Hi, Mike Chaglasian, Illinois College of Optometry, Illinois Eye Institute, where I'm associate professor and chief of staff. Here at the ARVO meeting in Seattle, where my poster was, "Detection of glaucoma with a novel widefield imaging device combined with OCT." So in this poster, we looked at a group of glaucoma individuals along with a group of normal individuals, and use the Optos Monaco device. This is a new device in the past few years that combines traditional ultra widefield fundus imaging along with spectral domain OCT. And in our study, we looked at 33 glaucoma subjects with a wide range of glaucoma severity, along with a matched age group of normal individuals. And we use the Monaco device to identify the detection of glaucoma as compared to the normal individuals. So we looked at the area under the ROC curves for sensitivities in the detection of glaucoma disease in our groups.

So, what we found for the results, for this small study, was that the strongest indicators of detecting glaucoma based on optic disk size was vertical CD ratio and rim area. They had ROCs is of 0.98 and 0.96. Also, average retinal nerve fiber layer thickness (RNFL) and inferior RNFL thickness were also very strong indicators of glaucoma disease. And then finally, in the last scan set was glaucoma ganglion cell complex, and this had a very strong indicator for average GCC values for detection of glaucoma. So in conclusion, this small study looked at a new device, the Monaco OCT combined with ultra widefield imaging from Optos, and we identified that it had a strong and positive ability to detect glaucoma as compared to normal individuals. And so the goal of this project was to identify this new and novel device is on par with our currently available technologies on OCT imaging to detect glaucoma at approximately the same rate as is reported in the literature. So practicing optometrists and ophthalmologists can feel confident that the Monaco OCT is going to do that glaucoma detection for them. Yeah, and the next step certainly would be to expand our subject size, since we had a small group here of just 33 individuals with glaucoma and 33 age-match normals. We will want to expand this to a larger database. My financial disclosure is that I do research work with Optos.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
© 2025 MJH Life Sciences

All rights reserved.